Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7808641 | PMC |
| http://dx.doi.org/10.1371/journal.ppat.1009093 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Public Health.
Alzheimers Dement
December 2024
Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Background: Alzheimer's disease (AD) is a neurodegenerative disorder with significant environmental factors, including diet, that influence its onset and progression. While the ketogenic diet (KD) holds promise in reducing metabolic risks and potentially affecting AD progression, only a few studies have explored the KD's molecular impact for markers of AD therapeutic potential. The BEAM diet study simultaneously profiled the KD's effect on the lipidome, blood and cerebrospinal metabolome, and microbiome of both cognitively impaired and cognitively normal individuals.
View Article and Find Full Text PDFBackground: Blood-based biomarkers for dementia are gaining attention due to their non-invasive nature and feasibility in regular healthcare settings. Here, we explored the associations between 249 metabolites with all-cause dementia (ACD), Alzheimer's disease (AD), and vascular dementia (VaD) and assessed their predictive potential.
Method: This study included 274,160 participants from the UK Biobank.
Developing Topics.
Alzheimers Dement
December 2024
University of California, Los Angeles, Los Angeles, CA, USA.
Background: Alzheimer's Disease (AD) is a chronic, incurable neurodegenerative condition characterized by extensive systemic, cellular, and molecular abnormalities. One such aspect recent studies have highlighted is the reduction in plasma branched-chain amino acid (BCAA) concentrations, identifying them as a potential emerging marker for the disease. Although BCAAs have been implicated in the pathogenesis of AD, their utility in clinical prognosis remains unexplored.
View Article and Find Full Text PDFDeveloping Topics.
Alzheimers Dement
December 2024
Vanderbilt Memory & Alzheimer's Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Background: Previous models of resilience to Alzheimer's Disease (AD) have relied on cross-sectional designs and inclusion of measures of neuropathology. Here, we present a novel modeling approach incorporating longitudinal data and the use of APOE and higher order interaction terms to approximate neuropathological resilience, vastly increasing participant diversity and statistical power. We validate this approach and report novel genetic associations with neuropathological resilience.
View Article and Find Full Text PDFDrug Development.
Alzheimers Dement
December 2024
Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India.
Background: The present study recapitulates the potency of the novel synthesized piperazine-benzoquinone derivative as a lead molecule selectively targeting AChE along with the antioxidative potential for the management of cognitive decline in Alzheimer's disease.
Method: Novel piperazine-benzoquinone derivative was synthesized implementing appropriate synthetic procedures and was characterized by various spectral and elemental techniques. The purity of this synthetic analogue was ascertained by TLC, melting point determination and elemental analyses.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!